Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer

摘要

Currently, pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease despite advances in multimodality therapy. The majority of patients with PDAC present with locally advanced or metastatic disease, and additional therapies or treatment paradigms are needed to improve progression-free survival and overall survival. Alternate therapies, such as a nanoparticle albumin-bound form of paclitaxel, epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and poly(ADP-ribose) polymerase (PARP)1/2 inhibitors have been investigated for potential synergy with systemic agents in PDAC. Here, we review the current status of radiotherapy combined with systemic therapies for pancreatic cancer, with a focus on these targeted agents, novel immunotherapies, and discussion of the Abscopal effect.